LabCorp and Envigo Sign Innovative Agreement to Expand Covance’s Nonclinical Drug Development Capabilities and Create an Independent Research Models and Services Provider

Expands nonclinical drug development global reach and capabilities with addition of Envigo’s Contract Research Services

Combines two complementary businesses into a new comprehensive research models and services provider under the Envigo brand

Strategic Fit

- Simplifies and focuses Covance’s nonclinical research business model
- Enhances Covance’s nonclinical capabilities with additional scientific and technical expertise, including respiratory
- Adds facilities in Europe and the U.S. East Coast to meet growing client needs

- Combines two complementary premier suppliers of research models and services
- Enables clients to more easily source the best models to meet clients’ research needs

Multi-year, renewable strategic supply agreement provides clients access to their current high-quality research models and services, as well as expanded access to full range of nonclinical offerings from both providers
### Provider Capabilities after Transaction Close

#### Covance Early Development

- 4,200 Employees
- 13 Locations in 7 Countries

<table>
<thead>
<tr>
<th>Capability</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global Safety Assessment</td>
<td>59%</td>
</tr>
<tr>
<td>Global Drug Metabolism and Pharmacokinetics</td>
<td>34%</td>
</tr>
<tr>
<td>Global Chemical &amp; Crop Protection</td>
<td>7%</td>
</tr>
</tbody>
</table>

#### Envigo

- 1,200 Employees
- >20 Locations in 8 Countries

<table>
<thead>
<tr>
<th>Capability</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research model support services</td>
<td>35%</td>
</tr>
<tr>
<td>Genetic testing</td>
<td></td>
</tr>
<tr>
<td>Surgical services</td>
<td></td>
</tr>
<tr>
<td>Diet, bedding and enrichment</td>
<td></td>
</tr>
</tbody>
</table>

### Complementary Offerings after Transaction Close

#### Covance Early Development

- General toxicology
- Genetic toxicology
- Safety pharmacology
- Immunology and immunotoxicology solutions
- Immunology services
- Developmental and reproductive toxicology
- Metabolism and PKPD modeling
- Specialty
  - Ocular
  - Respiratory
  - Infusion
- Pathology
- Pharma consultancy
- Pharmacology models
- Bioanalytical
- Chemistry, Manufacturing and Controls
- Archiving

#### Envigo

- Rodents
- Canines
- Rabbits
- Non-human primates
- Contract breeding
- Biological products and services

### Research-Focused Client Base after Transaction Close

#### Covance Early Development

- 34% Global Drug Metabolism and Pharmacokinetics

#### Envigo

- 35% Academia
- 5% Government
- 25% Biopharma

---

*This transaction creates a best-of-both-worlds situation for customers — two leading providers with expanded capabilities and reach, each with a dedicated core focus. As a result, we can create growth opportunities for our exceptional people.*

— John Ratliff, CEO, Covance

*We have made a bold move for our customers and employees by creating a new industry offering. We are committed to providing the highest-quality research models to help build a healthier and safer world.*

— Dr. Adrian Hardy, President and CEO, Envigo